Loading, Please Wait...

CST: 20/11/2019 03:26:36   

Athenex to Host Conference Call with Key Opinion Leader Following Oral Presentation of Phase III Results of KX2-391 Ointment in the Treatment of Actinic Keratosis at the American Academy of Dermatology Annual Meeting

267 Days ago

Seth B. Forman, MD, CEO of ForCare Medical Group and ForCare Clinical Research, to participate in a call on Monday, March 4, 2019 at 8:30am ET

BUFFALO, N.Y., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will host a conference call and webcast with a Key Opinion Leader (KOL) on Monday, March 4, 2019 at 8:30am Eastern Time, following the late-breaking oral presentation on the results from two Phase III studies of KX2-391 ointment in the treatment of actinic keratosis (AK) at the 2019 American Academy of Dermatology Annual Meeting.

The call will feature a presentation by KOL Seth B. Forman, MD, practicing dermatologist at ForCare Medical Group and ForCare Clinical Research, who will discuss the medical need in actinic keratosis, the treatment landscape and current treatment options, and the results of the two KX2-391 Phase III studies. He will be available to answer questions at the conclusion of the call.

Athenex’s management team will also review the highlights of the efficacy and safety results from the two Phase III studies as well as provide an overview of the company's ongoing development and commercialization of KX2-391 ointment.

Dr. Seth B. Forman is the founder and Chief Executive Officer of the ForCare Medical Group and ForCare Clinical Research in Florida.  He is a practicing physician and has provided patient care for 12 years.  He has also acted as an investigator in the Phase II and Phase III trials of KX2-391 ointment in the treatment of actinic keratosis. He is Board Certified in Dermatology and Dermatopathology. Dr. Forman’s research has led to his writing numerous peer-reviewed articles about various dermatological issues in select publications such as the New England Journal of Medicine, The Journal of the American Academy of Dermatology and The Journal of Cutaneous Pathology. Dr. Forman is the winner of the AAMC/Pfizer Caring for Community Grant, American Cancer Society Community Service Grant and Mellette Cancer Scholarship. He is a member of the American Academy of Dermatology, Hillsborough County Medical Association and The American Medical Association. Dr. Forman is also a Regional Board Member for the American Cancer Society, Board Chair of Hillel Academy and has served as Board Member of The Liaison Committee for Medical Education, The Medical College of Virginia.

Conference Call and Live Webcast
Monday, March 4, 2019 @ 8:30am Eastern Time
Domestic:   877-407-0784
International:   201 689 8560
Conference ID:   13687989
Webcast:   http://public.viavid.com/index.php?id=133438

A live audio webcast will be available on the Events page of the Investor Relations section of Athenex’s website at www.athenex.com. A replay of the audio webcast will be available on Athenex’s website following the call.

Details for the AAD presentation are as follows:
Title:    KX2-391 Ointment 1%, a Novel Dual Src/Tubulin Inhibitor, is Efficacious and Safe in the Treatment of Adults with Actinic Keratosis in Two Phase III Studies
Session:   S034 (Late-breaking Research: Clinical Trials)
Date and Time:   Saturday, March 2, 2019 at 3:40pm Eastern Time
Location:   Ballroom A at the Walter E. Washington Convention Center

About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery and development of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on non-absorbed P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments.  Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; and multiple locations in Chongqing, China. For more information, please visit www.athenex.com.

CONTACTS
Investor Relations:
Tim McCarthy
Managing Director, LifeSci Advisors, LLC
Tel: +1 716-427-2952
Direct: +1 212-915-2564

Athenex, Inc.:
Randoll Sze
Chief Financial Officer
Email: randollsze@athenex.com  

Jacqueline Li
Corporate Development and Investor Relations
Email: jacquelineli@athenex.com 

Is your business listed correctly on America’s largest city directory network of 1,000 portals?